CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease Oct 05, 2017 6:00am EDT
CytoDyn to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 07, 2017 5:35pm EDT
CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV Sep 06, 2017 6:00am EDT
CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV Aug 21, 2017 6:00am EDT
CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial Aug 09, 2017 6:00am EDT
CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 Jun 01, 2017 6:00am EDT
CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease May 17, 2017 6:00am EDT
Potential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA Apr 17, 2017 6:00am EDT
Reminder: CytoDyn to Hold Investment Community Conference Call April 18, 2017 Apr 13, 2017 4:10pm EDT
